FY2024 EPS Estimates for Entera Bio Reduced by HC Wainwright

Entera Bio Ltd. (NASDAQ:ENTX) – Equities researchers at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for shares of Entera Bio in a research report issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.28) per share for the year, down from their prior forecast of ($0.23). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Entera Bio’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Entera Bio’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.55) EPS.

Entera Bio Stock Up 4.8 %

NASDAQ ENTX opened at $1.75 on Thursday. The company has a 50 day moving average price of $1.85 and a 200 day moving average price of $1.92. Entera Bio has a 52 week low of $0.52 and a 52 week high of $3.35. The firm has a market cap of $62.62 million, a PE ratio of -6.73 and a beta of 1.58.

Institutional Trading of Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC acquired a new stake in Entera Bio Ltd. (NASDAQ:ENTX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,040 shares of the company’s stock, valued at approximately $37,000. Institutional investors and hedge funds own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.